Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study

Background: Cancer patients with atrial fibrillation (AF) were excluded in the major clinical trials. We therefore investigated the efficacy and safety of novel oral anticoagulant (NOAC) versus warfarin in these patients. Methods: Data were retrieved from Taiwan National Health Insurance Research Da...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Victor Chien-Chia, Wang, Chun-Li, Huang, Yu-Tung, Lan, Wen-Ching, Wu, Michael, Kuo, Chang-Fu, Chen, Shao-Wei, Chu, Pao-Hsien, Wen, Ming-Shien, Kuo, Chi-Ching, Chang, Shang-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930400/
https://www.ncbi.nlm.nih.gov/pubmed/31892976
http://dx.doi.org/10.7150/jca.36468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930400/
https://www.ncbi.nlm.nih.gov/pubmed/31892976
http://dx.doi.org/10.7150/jca.36468

Ejemplares similares